Market Research Logo

Global Biopolar Disorder Therapeutics Market 2015-2019

About bipolar disorder therapeutics

Bipolar disorder is a psychological disorder characterized by intermittent mood swings. The individual suffering with this disorder experiences extreme poles of either mania or depression or both. The disorder severely affects the personal, social, and professional life of an individual. The symptoms usually include drastic changes in mood, either as a manic episode or a depressive episode. There is no complete cure for the disorder. Atypical antipsychotics, mood stabilizers, and antidepressants are being widely used in for treatment. It is considered as a lifelong disease and the discontinuation of the medication can lead to relapse of the condition.

Technavio's analysts forecast the global bipolar disorder therapeutics market to grow at a CAGR of 2.24% over the period 2014-2019.

Covered in this report

The report covers the present scenario and growth prospects of the global bipolar disorder therapeutics market for 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of bipolar disorder.

Technavio's report, Global Bipolar Disorder Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, APAC, and EMEA; it also covers the landscape of the global bipolar disorder therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA
Key vendors
  • Allergan
  • AstraZeneca
  • BMS
  • Eli Lilly
  • GlaxoSmithKline
  • Janssen Pharmaceuticals
Other prominent vendors
  • AbbVie
  • Abital Pharma
  • Astellas
  • Convergence Pharmaceuticals
  • D Pharm
  • Delpor
  • Gedeon Richter
  • H. Lundbeck
  • Intra-Cellular Therapies
  • Novartis
  • Noven Pharmaceuticals
  • Omeros Corporation
  • Otsuka
  • Pfizer
  • PNBDevCo
  • Reviva Pharmaceuticals
  • SK Biopharmaceuticals
  • Sunovion Pharmaceutical
Key market driver
  • Increase in prevalence of bipolar disorder
  • For a full, detailed list, view our report
Key market challenge
  • Use of alternative therapies
  • For a full, detailed list, view our report
Key market trend
  • Rise in public awareness
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Biopolar Disorder Therapeutics Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Biopolar Disorder Therapeutics Market: Allergan, AstraZeneca, BMS, Eli Lilly, GSK and Janssen Pharmaceuticals
Other Prominent Vendors in the market are: AbbVie, Abital Pharma, Astellas, Convergence Pharmaceuticals, D Pharm, Delpor, Gedeon Richter, H. Lundbeck, Intra-Cellular Therapies, Novartis, Noven Pharmaceuticals, Omeros Corporation, Otsuka, Pfizer, PNBDevCo, Reviva Pharmaceuticals, SK Biopharmaceuticals, and Sunovion Pharmaceutical.
Commenting on the report, an analyst from Technavio’s team said: “The rise in awareness about the disorder has led to increased understanding among the public. This has led to a rise in the number of individuals seeking medical attention for the treatment of the disorder. Also, strategic alliances formed between vendors help in increased penetration of the drugs in the market and increase market share.”
According to the report, an increase in the patient pool has been observed due to the increased identification of the disease because of awareness programs. Current treatment options do not provide a cure for the disorder, therefore, there is a significant unmet need in the market. Drugs that can cause remission of depression and mania in patients are therefore expected to drive the growth of the market.
Further, the report states that the lack of availability of diagnostic procedures for the identification of the disorder is a major challenge faced by the bipolar disorder therapeutics market.

Companies Mentioned

Allergan, AstraZeneca, BMS, Eli Lilly, GSK, Janssen Pharmaceuticals, AbbVie, Abital Pharma, Astellas, Convergence Pharmaceuticals, D Pharm, Delpor, Gedeon Richter, H. Lundbeck, Intra-Cellular Therapies, Novartis, Noven Pharmaceuticals, Omeros Corporation, Otsuka, Pfizer, PNBDevCo, Reviva Pharmaceuticals, SK Biopharmaceuticals, Sunovion Pharmaceutical.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Disease overview
    • Understanding the disorder
    • Types of bipolar disorder
    • Causes
    • Signs and symptoms
      • Table Signs and symptoms of bipolar disorder
      • Table Signs and symptoms of mania
      • Table Signs and symptoms of depression
    • Management
      • Table Treatment options for bipolar disorder
      • Table Medications for treating bipolar disorder
    • Self-help
    • Epidemiology
  • Pipeline analysis
    • Table Global bipolar disorder therapeutics market: Pipeline portfolio
    • ITI-007
    • FK949E
    • PROCYCLOX
    • RP5603
    • CNV1061436
    • LY2979165
    • DP-VPA
    • SKL-PSY
    • PGW-5
    • DLP-114
    • DLP-115
    • Small molecule targeting GPR78
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global bipolar disorder therapeutics market 2014-2019 ($ millions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by drug class
    • Table Segmentation of global bipolar disorder therapeutics market by drug class
    • Mood stabilizers
    • Anticonvulsants
    • Atypical antipsychotics
    • Antidepressant drugs
    • Anti-anxiety drugs
  • Market segmentation by mechanism of action
    • Selective serotonin reuptake inhibitors
    • Serotonin-norepinephrine reuptake inhibitors
    • Tricyclic antidepressants
    • Monoamine oxidase inhibitors
    • Benzodiazepines
    • Beta blockers
    • Others
  • Geographical segmentation
    • Global bipolar disorder therapeutics market by geographical segmentation 2014-2019
      • Table Global bipolar disorder therapeutics market segment by geography 2014
      • Table Bipolar disorder therapeutics market revenue by geography 2014-2014 ($ millions)
    • Bipolar disorder therapeutics market in Americas
      • Table Bipolar disorder therapeutics market in Americas 2014-2019 ($ millions)
    • Bipolar disorder therapeutics market in EMEA
      • Table Bipolar disorder therapeutics market in EMEA 2014-2019 ($ millions)
    • Bipolar disorder therapeutics market in APAC
      • Table Bipolar disorder therapeutics market in APAC 2014-2019 ($ millions)
  • Market drivers
    • Increase in prevalence of bipolar disorder
    • High unmet need
    • Increase in R&D
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Use of alternative therapies
    • Lack of availability of standard diagnostic methods
      • Table Common disorders that co-exist with bipolar disorder
    • Limited awareness of disease
    • Increase in patent expiries
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Rise in public awareness
    • Patient assistance programs
    • Strategic alliances
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2014
      • Table Market share analysis of global bipolar disorder therapeutics market 2014
      • Table YoY growth rate of major bipolar disorder drugs 2014-2019 ($ millions)
      • Table Bristol-Myers Squibb: YoY growth and revenue generated from net product sales of Abilify 2011-2014 ($ millions)
      • Table Bristol-Myers Squibb: Percentage share of Abilify in US and non-US region based on revenue 2014
      • Table Bristol-Myers Squibb: Key takeaways
      • Table AstraZeneca: YoY growth and revenue generated from net product sales of Seroquel XR 2011-2014 ($ millions)
      • Table AstraZeneca: Revenue generated from sales of Seroquel XR by region 2014 ($ millions)
      • Table AstraZeneca: YoY growth and revenue generated from net product sales of Seroquel IR 2011-2014 ($ millions)
      • Table AstraZeneca: Key takeaways
      • Table Janssen Pharmaceuticals: YoY growth and revenue generated from net product sales of Risperdal Consta 2011-2014 ($ millions)
      • Table Janssen Pharmaceuticals: Key takeaways
      • Table Eli Lilly: YoY growth and revenue generated from net product sales of Zyprexa 2011-2014 ($ millions)
      • Table Eli Lilly: Key takeaways
      • Table GlaxoSmithKline: YoY growth and revenue generated from net product sales of Lamictal 2011-2014 ($ millions)
      • Table GlaxoSmithKline: Revenue generated from sales of Lamictal by region 2014 ($ millions)
      • Table GlaxoSmithKline: Key takeaways
      • Table Allergan: Key takeaways
    • Other prominent vendors
  • Key vendor analysis
    • Allergan
      • Table Allergan: Business segmentation by product revenue 2014
      • Table Allergan: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Allergan: Geographical segmentation by revenue 2014
    • AstraZeneca
      • Table AstraZeneca: Business segmentation by revenue 2014
      • Table AstraZeneca: Business segmentation by revenue 2013 and 2014
      • Table AstraZeneca: Geographical segmentation by revenue 2014
    • BMS
      • Table BMS: Segmentation by revenue 2014
      • Table BMS: Segmentation by revenue 2013 and 2014 ($ billions)
      • Table BMS: Geographical segmentation by revenue 2014
    • Eli Lilly
      • Table Lilly: Business segmentation by revenue 2014
      • Table Eli Lilly: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Eli Lilly: Geographical segmentation by revenue 2014
    • GSK
      • Table GSK: Business segmentation by revenue 2014
      • Table GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table GSK: Geographical segmentation by revenue 2014
    • Janssen Pharmaceuticals
      • Table Janssen Pharmaceuticals: Key therapeutic areas
  • Appendix
    • List of abbreviatios
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report